BD (NYSE:BDX) and Ypsomed today announced a strategic collaboration to advance self-injection solutions for high-viscosity biologic drugs. In a joint project, the companies pre-assessed and streamlined the integration of the BD Neopak XtraFlow glass prefillable syringe with the Ypsomed YpsoMate 2.25 auto-injector platform. They aim to address current limitations by enabling the delivery of higher-viscosity […]
Ypsomed
Ypsomed increases auto-injector production in Germany
Ypsomed announced today that it opened a new production hall at its German site in Schwerin to increase auto-injector production. The Burgdorf, Switzerland-based company said its expansion enables an increase in production capacity to meet growing global demand. CEO Simon Michel also said the company plans to further expand the plant in the coming years. […]
Ypsomed reports positive outcomes with automated insulin delivery for maternal health
Ypsomed reports positive outcomes from a large, randomized trial of its closed-loop insulin delivery technology during type 1 diabetes pregnancy. The Switzerland-based company’s AiDAPT study demonstrated that hybrid closed-loop therapy significantly improves maternal glycemic control. Pregnant women with type 1 diabetes used the automated insulin delivery system based on the CamDiab CamAPS FX algorithm in […]
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
Ypsomed closes pen needle, BGM business sale to focus on insulin pump
Ypsomed announced today that it completed the sale of its pen needle and blood glucose monitoring (BGM) businesses to Medical Technology and Devices (MTD). The Burgdorf, Switzerland-based company first announced an agreement to sell off those businesses to MTD in March. Ypsomed plans to support a reliable transition to ensure pen needle supply amid the […]
Ypsomed inks autoinjector deal with German pharma company Medac
Ypsomed announced that German company Medac selected its autoinjector technology for the relaunch of its methotrexate pen. The YpsoMate 1.0 will gradually replace the current available metoject/metex pen for the German company’s methotrexate products. Ypsomed launched its new autoinjector in various countries during the first quarter of this year. Medac develops subcutaneous methotrexate (MTX) products, […]
Study highlights benefits of automated insulin delivery for children in UK
A study in the UK demonstrated significant improvements in HbA1c for users of automated insulin delivery technologies. This comes on the heels of a UK NHS initiative to provide tens of thousands of children and adults with type 1 diabetes in the country with an artificial pancreas. The study aimed to assess the efficacy of […]
Ypsomed, ten23 health collab on YpsoDose patch injector
Ypsomed announced today that it entered into a partnership with ten23 health to commercialize its YpsoDose wearable injector. Burgdorf, Switzerland-based Ypsomed designed YpsoDose for the subcutaneous self-injection of large-volume doses. ten23 health, a Swiss CDMO, offers drug development, filling and device assembly expertise to contribute to the product offering. The strategic collaboration sees both parties […]
Ypsomed sells pen needle, blood glucose monitor business to focus on insulin pump
Ypsomed announced today that it agreed to sell its pen needle and blood glucose monitoring (BGM) businesses to Medical Technology and Devices (MTD). With the transfer of these businesses, Ypsomed plans to focus its diabetes care business on insulin pumps. Specifically, it looks to the further development and marketing of the mylife Loop automated insulin […]
Ypsomed: closed-loop insulin dosing improves health of pregnant women with type 1 diabetes
Ypsomed today announced clinical study data demonstrating the benefits of its hybrid closed-loop insulin delivery system for pregnant women. Pregnant women with type 1 diabetes and their babies benefitted from the automated insulin delivery system based on the CamDiab CamAPS FX algorithm. The New England Journal of Medicine published these outcomes from Ypsomed’s AiDAPT clinical study. Ypsomed says […]
